STOCK TITAN
  1. Home
  2. News
  3. ALUR

Allurion Technologies, Inc. - ALUR STOCK NEWS

Welcome to our dedicated page for Allurion Technologies news (Ticker: ALUR), a resource for investors and traders seeking the latest updates and insights on Allurion Technologies stock.

Allurion Technologies, Inc. (NYSE: ALUR) is a pioneering medical device company committed to combating obesity through innovation. The company offers a comprehensive weight loss platform known as the Allurion Program, which includes the world's first and only swallowable, procedure-less intragastric balloon designed for weight loss. This unique solution, the Allurion Balloon, is delivered without the need for surgery, endoscopy, or anesthesia, making it a convenient and less invasive option for patients.

The Allurion Program is further enhanced by the Allurion Virtual Care Suite (VCS), a suite of AI-powered tools that aid in remote patient monitoring, proprietary behavior change programs, secure messaging, and video telehealth services. The virtual suite also includes the Allurion Mobile App for consumers, the Allurion Connected Scale, and Allurion Insights for healthcare providers featuring the Iris AI Platform. These components work synergistically to ensure a comprehensive and personalized weight loss journey for patients.

Recent achievements by Allurion include a significant partnership with the Somerset NHS Foundation Trust, making it the first NHS trust to introduce the Allurion Gastric Balloon. This partnership aims to provide rapid, effective weight loss solutions to those most in need, particularly patients with high BMIs who require rapid weight loss to qualify for lifesaving surgeries.

Clinical data supports the efficacy and safety of the Allurion Program, with studies showing an average weight loss of 10-15% of body weight over approximately four months. Impressively, around 96% of this weight loss can be sustained one year after the balloon passes. The program has demonstrated particular effectiveness in patients with higher BMIs, with weight loss percentages reaching up to 20% over six months for those with a BMI over 40.

Financially, Allurion has shown robust growth and potential, evidenced by a 30% increase in procedural volume, reflecting strong demand for their innovative solutions. The company's commitment to expanding its offerings and its strategic partnerships aims to address the growing obesity epidemic, which imposes significant financial burdens on healthcare systems worldwide.

Allurion's leadership team, led by Founder and CEO Dr. Shantanu Gaur, continues to drive the company forward with a clear vision and strategic direction, focusing on expanding their global footprint and enhancing patient outcomes through continuous innovation and partnerships.

News

Allurion to Participate in the Oppenheimer 34th Annual Healthcare MedTech & Services Conference

Rhea-AI Summary
Allurion Technologies, Inc. (ALUR) will be participating in the 34th Annual Oppenheimer Healthcare MedTech & Services Conference on March 12 - 13, 2024. The company's CEO and CFO will present at the event, with a live webcast available on their website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.04%
Tags
conferences
-
News

Allurion to Report Fourth Quarter 2023 Financial Results on March 21, 2024

Rhea-AI Summary
Allurion Technologies, Inc. (ALUR) will report Q4 2023 financial results on March 21, 2024. A conference call will follow to discuss results and provide a business update.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.31%
Tags
conferences earnings
-
News

Allurion to Participate in Cowen’s 44th Annual Health Care Conference

Rhea-AI Summary
Allurion Technologies, Inc. (ALUR) to participate in the 44th Annual Cowen Health Care Conference. CEO and CFO to present on March 5, 2024, at 9:50 a.m. Eastern Time.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.66%
Tags
conferences
News

Allurion to Participate in the BTIG Snowbird MedTech, Digital Health, Life Science and Diagnostic Tools Conference

Rhea-AI Summary
Allurion Technologies, Inc. (ALUR) will be participating in the BTIG Snowbird Conference from February 12-14, 2024. CEO Shantanu Gaur and CFO Chris Geberth will be available for investor 1x1 meetings.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1%
Tags
conferences
-
News

Brendan Gibbons Appointed Chief Legal Officer at Allurion Technologies

Rhea-AI Summary
Allurion Technologies, Inc. (NYSE:ALUR) has appointed Brendan Gibbons as its new Chief Legal Officer and corporate secretary. Brendan brings 20 years of experience as a legal and compliance officer at public companies, with his most recent role at Acushnet Company. In this new role, Brendan will lead the company’s legal and compliance strategies, guiding its global expansion and commitment to delivering safe and effective weight loss solutions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.1%
Tags
none
-
News

World first : Somerset NHS Foundation Trust Treats First Patients with Allurion Balloon for Pre-Surgical Weight Loss

Rhea-AI Summary
Allurion Technologies, Inc. has announced that Somerset NHS Foundation Trust is the first NHS trust in the UK to introduce the Allurion Gastric Balloon, a swallowable gastric balloon that requires no surgery, endoscopy, or anesthesia. The balloon helps patients lose 10-15% of their body weight in 4 months and is proven to be safe and effective. The Allurion Program is particularly effective for patients with a higher BMI and is expected to save the NHS significant time and money compared to bariatric surgery. The program also includes an AI-powered behavior change program and 1-1 support from doctors and nutritionists. The partnership between Allurion and the NHS addresses the need for scalable, evidence-based weight solutions in the UK.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.01%
Tags
none
News

Somerset NHS Foundation Trust Treats First Patients with Allurion Balloon for Pre-Surgical Weight Loss

Rhea-AI Summary
Allurion Technologies, Inc. (NYSE: ALUR) announced the introduction of the Allurion Gastric Balloon by the Somerset NHS Foundation Trust, marking the first time a non-private sector organization in the world has introduced this innovative swallowable gastric balloon. The balloon, which is filled and remains in the stomach for approximately 4 months, has been proven to help patients lose an average of 10-15% of their body weight. The treatment is expected to save the NHS significant time and money as it is substantially less expensive than bariatric surgery. The partnership between Allurion and the NHS aims to provide a weight loss solution that does not tap into surgical or endoscopic resources that are already overbooked and constrained.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.01%
Tags
none
-
News

Allurion's Virtual Care Suite Digital Platform Accelerates Commercial Expansion With New Strategic Partnerships

Rhea-AI Summary
Allurion Technologies, Inc. (ALUR) has expanded its Virtual Care Suite (VCS) digital platform with new commercial agreements signed with Lazeo and Transform, two of Europe’s largest aesthetic and weight loss groups. The VCS has shown positive results in increasing patient accountability, practice efficiency, and patient engagement, with clinics reporting an average 11% additional weight loss and over 16% additional patients reaching their goals. This expansion underscores the growing opportunities for the digital platform since launching Coach Iris—Allurion’s 24/7 AI-powered weight loss coach. The VCS now provides 24/7 coaching and guidance to patients across multiple modalities of care, including anti-obesity medications, devices, and bariatric surgery.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.72%
Tags
partnership
-
News

Allurion Announces Publication of Randomized, Double-Blind Study Demonstrating Significant Improvement in Obesity-Related Co-Morbidities

Rhea-AI Summary
Allurion Technologies, Inc. (NYSE: ALUR) announced the publication of a study demonstrating significant reductions in type 2 diabetes, hypertension, and obstructive sleep apnea in just 4 months on the Allurion Program. Weight loss was 13.7% at 4 months, with resolution of type 2 diabetes, hypertension, and obstructive sleep apnea observed in 55.5%, 58.8%, and 57.8%, respectively. Results improved with the addition of oral GLP-1 agonist semaglutide, with weight loss improving to 17.6% and co-morbidity resolution improving to 64.7%, 64.3%, and 72%, respectively.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.17%
Tags
none
News

Allurion Announces Preliminary Fourth Quarter and Full Year 2023 Results and Provides 2024 Outlook

Rhea-AI Summary
Allurion Technologies, Inc. (NYSE: ALUR) announces substantial procedure growth in 2023 driven by best-in-class efficacy of balloon program. The company also prioritizes key investments in strategic markets and digital innovations ahead of FDA milestones. Preliminary unaudited results for the fourth quarter and full year 2023 show a 30% procedure volume growth, reflecting significant demand for the Allurion Program. CEO Dr. Shantanu Gaur emphasizes the company's focus on reducing cost structure, optimizing capital structure, and accelerating the path to profitability in the 2024 outlook.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.33%
Tags
earnings

FAQ

What is the current stock price of Allurion Technologies (ALUR)?

The current stock price of Allurion Technologies (ALUR) is $0.348 as of December 20, 2024.

What is the market cap of Allurion Technologies (ALUR)?

The market cap of Allurion Technologies (ALUR) is approximately 18.7M.

What is the Allurion Program?

The Allurion Program is a comprehensive weight loss platform that includes the Allurion Gastric Balloon, the world's first swallowable, procedure-less gastric balloon, and the Allurion Virtual Care Suite featuring AI-powered tools for remote patient monitoring and behavior management.

How does the Allurion Gastric Balloon work?

The Allurion Gastric Balloon is a swallowable capsule that, once ingested, is filled and remains in the stomach for approximately four months, creating a feeling of fullness and helping patients lose 10-15% of their body weight on average.

What makes the Allurion Program unique?

The Allurion Program is unique because it combines a non-invasive gastric balloon with a suite of digital health tools, providing a comprehensive approach to weight loss that includes behavior modification, remote monitoring, and personalized support.

Is the Allurion Balloon safe?

Yes, the Allurion Balloon is supported by over 30 peer-reviewed studies indicating it is a safe and effective method for weight loss. It does not require surgery, endoscopy, or anesthesia.

Who can benefit from the Allurion Program?

The Allurion Program is particularly beneficial for individuals with a higher BMI (Body Mass Index) who are seeking a rapid, non-surgical weight loss solution to improve their health and qualify for further medical treatments.

What recent achievements has Allurion accomplished?

Allurion recently partnered with the Somerset NHS Foundation Trust, the first NHS trust to introduce the Allurion Gastric Balloon, aiming to provide effective weight loss solutions quickly and efficiently.

What are the components of the Allurion Virtual Care Suite?

The Allurion Virtual Care Suite includes the Allurion Mobile App, Allurion Insights for healthcare providers, the Iris AI Platform, and the Allurion Connected Scale, all designed to support and monitor patients' weight loss journeys remotely.

How effective is the Allurion Program?

Studies show that the Allurion Program helps patients lose an average of 10-15% of their body weight in four months, with around 96% of this weight loss sustained one year after the balloon passes.

What support does Allurion offer to healthcare providers?

Allurion provides healthcare providers with access to Allurion Insights, the Iris AI Platform, and comprehensive support tools through the Virtual Care Suite to customize and monitor weight loss therapy for their patients.

What is the financial outlook for Allurion?

Allurion has shown strong growth in procedural volume and revenue, reflecting increasing demand for their solutions. They are strategically expanding their global presence and enhancing patient outcomes through ongoing innovation and partnerships.

Stock ALUR logo
Allurion Technologies, Inc.

NYSE:ALUR

ALUR Rankings

#5338 Ranked by Market Cap
N/A Ranked by Dividends

ALUR Stock Data

18.71M
47.97M
26.03%
31.01%
1.41%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States of America
NATICK